Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Your Gut Bacteria May Reveal How Cancer Treatment Will Affect You (opens in a new tab)

scitechdaily.com · 2026-10-10

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. 4 other points were not covered by the paper.

  • 2 supported
  • 1 not supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim isn't supported by the study. Two of seven check out. Four claims the study doesn't address.

  • 2 supported
  • 1 not supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not supportedYounger breast cancer patients had a different microbial profile from those diagnosed later in life, with changes across 64 bacterial species, including lower levels of primary bile acids and higher levels of Clostridium scindens.View evidenceHide evidence

As stated64 bacterial species

Why this verdict

The profile supports early-onset breast cancer associations with lower fecal bile acids, but it reports reduced/lower Clostridium scindens, whereas the story states higher C. scindens. The profile also does not verify the stated '64 bacterial species' or 'primary bile acids' detail at abstract depth.

1

Study evidence

Within breast-cancer cases, early-onset disease was associated with lower fecal bile acid levels and reduced abundance of Clostridium scindens.

“Within cancer classes, we found lower levels of fecal bile acids and C. scindens in early-onset breast cancer and elevated lactate and Veillonella parvula in early-onset colorectal cancer.”
Claim 2 of 7Not coveredGut bacteria may hold clues to cancer survival and chemotherapy side effects before treatment even begins.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a gut-microbiome association with 5-fluorouracil diarrhea via DPD-encoding Anaerostipes hadrus, but it does not report survival findings or establish that these signals apply 'before treatment even begins.' The lead is hedged, but the survival and timing portions are not verifiable from the supplied abstract profile.

1

Study evidence

Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5‑fluorouracil‑induced diarrhea.

“Additionally, Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5-fluorouracil-induced diarrhea.”
Claim 3 of 7Not coveredThe Mayo Clinic study analyzed stool samples from 1,364 patients with cancer, linked them to clinical records, and the study appears in Cell.View evidenceHide evidence

As stated1,364 patients

Why this verdict

The supplied profile supports the Mayo Clinic Cancer Microbiome cohort size of 1,364 cancer patients and indicates clinical/demographic variables were used. However, the abstract profile does not directly verify linkage to clinical records as phrased or the publication venue claim that the study appears in Cell.

1

Study evidence

A confounder-aware analysis of the cohort identified 341 cancer-associated gut bacterial species across five cancer classes.

“real-world mixed-cancer cohort (Mayo Clinic Cancer Microbiome), comprising 1,364 cancer patients and 287 healthy controls”
2

Study evidence

The Mayo Clinic Cancer Microbiome cohort is a real-world mixed-cancer resource of 1,364 cancer patients and 287 healthy controls, presented by the authors as a foundational dataset for discovering cancer-specific microbiome signatures and predictive biomarkers.

“real-world mixed-cancer cohort (Mayo Clinic Cancer Microbiome), comprising 1,364 cancer patients and 287 healthy controls.”
Claim 4 of 7Not coveredResearchers identified gut bacteria associated with survival in colorectal, liver and intrahepatic bile duct, ovarian, prostate cancers, and melanoma; in liver and intrahepatic bile duct cancers, Bifidobacterium longum was associated with longer survival and Blautia A massiliensis with shorter survival.View evidenceHide evidence

Why this verdict

The supplied abstract profile does not report survival analyses, survival-associated bacteria, Bifidobacterium longum, or Blautia A massiliensis. These claims may require full-text evidence, but they are not verifiable from the provided abstract-level profile.

Claim 5 of 7Not coveredAmong patients receiving 5-fluorouracil, those who later developed diarrhea had lower levels of bacterial genes capable of breaking down the drug, with much of that capacity coming from Anaerostipes hadrus; this link was not seen with carboplatin.View evidenceHide evidence

Why this verdict

The abstract profile supports a related finding: Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5-fluorouracil-induced diarrhea. However, it does not verify the story’s more specific phrasing about patients who later developed diarrhea having lower levels of bacterial drug-breakdown genes, that much of the capacity came from A. hadrus, or the comparison that the link was not seen with carboplatin.

1

Study evidence

Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5‑fluorouracil‑induced diarrhea.

“Additionally, Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5-fluorouracil-induced diarrhea.”
Claim 6 of 7SupportedMayo Clinic researchers found higher levels of lactate and Veillonella parvula in adults diagnosed with colorectal cancer at 50 or younger than in patients diagnosed later in life.View evidenceHide evidence

Why this verdict

The paper profile reports that early-onset colorectal cancer was associated with elevated fecal lactate and increased Veillonella parvula abundance. The abstract profile does not spell out the exact age cutoff, but the story’s comparison of younger versus later-onset colorectal cancer matches the reported direction and framing.

1

Study evidence

Within breast-cancer cases, early-onset disease was associated with lower fecal bile acid levels and reduced abundance of Clostridium scindens.

“Within cancer classes, we found lower levels of fecal bile acids and C. scindens in early-onset breast cancer and elevated lactate and Veillonella parvula in early-onset colorectal cancer.”
Claim 7 of 7SupportedAfter comparing cancer patients with 287 people without cancer and accounting for other health conditions, the team identified 341 bacterial species associated with five cancer groups.View evidenceHide evidence

As stated341 bacterial species; 287 people without cancer

Why this verdict

The abstract profile states that the cohort included 1,364 cancer patients and 287 healthy controls and that a framework accounting for comorbidities and demographic/clinical variables identified 341 cancer-associated species across five cancer classes.

1

Study evidence

A confounder-aware analysis of the cohort identified 341 cancer-associated gut bacterial species across five cancer classes.

“real-world mixed-cancer cohort (Mayo Clinic Cancer Microbiome), comprising 1,364 cancer patients and 287 healthy controls”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Early-onset breast cancer was associated with lower fecal bile acids and reduced abundance of Clostridium scindens.

    The story reflects lower bile acids but reverses the direction for Clostridium scindens, saying it was higher rather than reduced. The stated 64-species detail is also not present in the abstract profile.

    From stratified observational analysis within cancer classes

6 things the story did carry across
  • The Mayo Clinic Cancer Microbiome cohort comprised 1,364 cancer patients and 287 healthy controls and was analyzed as a real-world mixed-cancer cohort.
  • The primary analysis used a framework intended to account for non-specific microbiome associations with cancer, comorbidities, and demographic/clinical variables, identifying 341 cancer-associated species across five cancer classes.
  • Early-onset colorectal cancer was associated with elevated fecal lactate and increased Veillonella parvula abundance.
  • Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was associated with protection against 5-fluorouracil-induced diarrhea.
  • The paper frames the cohort as a foundational resource for discovering cancer-specific microbiome signatures and predictive biomarkers.
  • Observational cohort design limits causal inference; reported associations do not establish causality and may be affected by residual confounding.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoIdentify cancer-specific gut microbiome species signatures across multiple cancer classes while accounting for confounding by comorbidities and demographic/clinical variables in a large real-world cohort.observational cohort / case-control comparisonsExpand

In plain English

Observational analysis of a real-world mixed-cancer cohort (Mayo Clinic Cancer Microbiome; 1,364 cancer patients, 287 healthy controls) that applied a framework to account for non-specific microbiome associations with cancer, comorbidities, and demographic/clinical variables and identified 341 cancer-associated gut bacterial species across five cancer classes.

Key findings

  • A confounder-aware analysis of the cohort identified 341 cancer-associated gut bacterial species across five cancer classes.
  • Early-onset breast cancer was associated with lower fecal bile acids and reduced abundance of Clostridium scindens.
“real-world mixed-cancer cohort (Mayo Clinic Cancer Microbiome), comprising 1,364 cancer patients and 287 healthy controls”
What this piece can’t prove
  • Observational cohort design limits causal inference; reported associations do not establish causality.
  • Real-world, mixed-cancer cohort heterogeneity and potential residual confounding (despite the stated adjustment framework) may affect specificity of reported cancer-associated species.

1 further detail could not be confirmed from the summary.

2human in vivoCharacterize within-cancer-class metabolite/microbial features implicated in early-onset cancers (e.g., bile acids/C. scindens in early-onset breast cancer; lactate/Veillonella parvula in early-onset colorectal cancer).stratified observational analysis within cancer classesExpand

In plain English

In stratified within-cancer-class analyses of a mixed-cancer real-world cohort, the authors report that early-onset breast cancer cases had lower fecal bile acid levels and reduced abundance of Clostridium scindens, whereas early-onset colorectal cancer cases showed elevated fecal lactate and increased Veillonella parvula abundance.

Key findings

  • Within breast-cancer cases, early-onset disease was associated with lower fecal bile acid levels and reduced abundance of Clostridium scindens.
  • Within colorectal-cancer cases, early-onset disease was associated with elevated fecal lactate and higher abundance of Veillonella parvula.
“Within cancer classes, we found lower levels of fecal bile acids and C. scindens in early-onset breast cancer and elevated lactate and Veillonella parvula in early-onset colorectal cancer.”
What this piece can’t prove
  • Observational, stratified analyses cannot establish causality and may be affected by confounding or selection biases.

2 further details could not be confirmed from the summary.

3human in vivoAssociate microbiome functional potential (e.g., Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase) with risk of chemotherapy adverse events (5-fluorouracil-induced diarrhea).observationalExpand

In plain English

In a real-world mixed-cancer cohort, the authors report that Anaerostipes hadrus carrying a dihydropyrimidine dehydrogenase (DPD) gene was associated with protection against 5‑fluorouracil (5‑FU)‑induced diarrhea.

Key findings

  • Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5‑fluorouracil‑induced diarrhea.
“Additionally, Anaerostipes hadrus encoding dihydropyrimidine dehydrogenase was protective against 5-fluorouracil-induced diarrhea.”
What this piece can’t prove
  • Unclear whether the protective association was consistent across cancer types or driven by a subset of patients.
  • Unclear if functional gene detection was validated or quantified at the strain/gene level versus inferred from taxonomic assignment.

1 further detail could not be confirmed from the summary.

4otherEstablish and present the Mayo Clinic Cancer Microbiome cohort as a foundational real-world resource (cancer patients plus healthy controls) for future biomarker discovery.real-world mixed-cancer cohortExpand

In plain English

The paper presents the Mayo Clinic Cancer Microbiome, a real-world mixed-cancer cohort comprising 1,364 cancer patients and 287 healthy controls, and frames this cohort as a foundational resource for discovery of cancer-specific microbiome signatures and predictive biomarkers.

Key findings

  • The Mayo Clinic Cancer Microbiome cohort is a real-world mixed-cancer resource of 1,364 cancer patients and 287 healthy controls, presented by the authors as a foundational dataset for discovering cancer-specific microbiome signatures and predictive biomarkers.
“real-world mixed-cancer cohort (Mayo Clinic Cancer Microbiome), comprising 1,364 cancer patients and 287 healthy controls.”
What this piece can’t prove
  • Abstract does not detail cohort ascertainment methods, inclusion/exclusion criteria, recruitment timeframe, or representativeness relative to target populations.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 39 candidate papers

Candidate

Author response for "Metal anchoring strategy: electrochemical sensor with excellent performance in gastrointestinal secretions"

2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.